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The dimeric cyclic enkephalin analog, (H-Tyr-D-I+-Gly-Phe-G\u-NH&, was isolated as a second major 
component from the crude product obtained in a solid-phase synthesis of the corresponding cyclic 
monomer, H-Tyr-D-Lys-Gly-Phe-G\u-NH,. In comparison with [Leusjenkephalin the cyclic dimer is about 
equipotent in assays representative for p-opioid receptor interactions and l/10 as potent at the d-receptor. 
The fact that the enkephalin dimer shows a receptor selectivity pattern distinct from that of the cyclic 
monomer and of the corresponding linear analog suggests that cyclodimerization via side-chain linkages 
might be generally useful as a means to produce shifts in the activity profiles of peptide hormones and neu- 
rotransmitters. 
Opioidpeptide Receptor selectivity Cyclic enkephalin dimer Solid-phase synthesis 
1. INTRODUCTION 
Conformational restriction of the opioid peptide 
enkephalin (H-Tyr-Gly-Gly-Phe-Met(or Leu)-OH) 
through cyclizations via side-chains resulted not 
only in highly potent analogs [ 1,2], but also in 
compounds showing greatly improved selectivity 
towards either S- or p-opioid receptors [3,4]. In a 
recently performed synthesis of the cyclic tetrapep- 
tide H-Tyr-D-Ofn-Gly-Glu-NH2 cyclization be- 
tween the side-chain amino and carboxyl groups of 
Orn and Glu on the benzhydrylamine resin pro- 
duced the side-chain-linked antiparallel cyclic 
dimer (H-Tyr-D-OIn-Gly-Glp-NH& aside from 
the cyclic monomer due to intersite reaction [S]. 
Both the cyclic monomer and the cyclic dimer 
Abbreviations: BAW, n-BuOH/AcOH/HzO (4: 1: 5, 
organic phase); Boc, t-butoxycarbonyl; BPAW, n- 
BuOH/pyridine/AcOH/H20 (15 : 10 : 3 : 12); DAGO, H- 
Tyr-D-Ala-Gly-Phe(NMe)-Gly-01; DSLET, H-Tyr-D- 
Ser-Gly-Phe-Leu-Thr-OH; FAB, fast atom bombard- 
ment; GPI, guinea pig ileum; MVD, mouse vas deferens 
showed very weak opioid activity in vitro [6]. Here 
we describe the properties of a side-chain-linked 
antiparallel cyclic dimer of an enkephalin-related 
peptide, (H-Tyr-D-Lys-Gly-Phe-G&-NH& (1) 
(fig.l), which was identified as a second major 
component in the crude product resulting from a 
recently repeated synthesis of the corresponding 
cyclic monomer, H-Tyr-D-Lys-Gly-Phe-G\u-NH2 
(2). This novel type of peptide dimer contains a 
36-membered ring structure and is characterized by 
a 2-fold symmetry axis. Opioid activities of the 
cyclic dimer and monomer were compared with 
those of the corresponding open-chain analog H- 
H-Tyr-D-Lys -tGly-+Phe~Glu-NH2 
A” 
0 do 
A3 Ii” 
I I 
pHN-Glu+Phe-Gly +-D-Lys+Tyr-H 
Fig. 1. Structural formula of the side-chain-linked 
antiparallel cyclic dimer of enkephalin, (H-Tyr-D- 
Qs-Gly-Phe-Glu-NH& 1. 
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Tyr-D-Nle-Gly-Phe-Gin-NH2 (3) in the GPI assay 
&receptor representative) and MVD assay (&re- 
ceptor representative) and in binding assays based 
on displacement of [3H]DAG0 k-selective) and 
[3H]DSLET (J-selective) from rat brain membrane 
preparations. 
2. MATERIALS AND METHODS 
The cyclic dimer (1) and the cyclic monomer (2) 
were isolated as the 2 major components of a 
product resulting from a solid-phase synthesis 
based on a scheme detailed in [5]. HPLC analysis 
of the crude product indicated that during the 
cyclization step 60% of the peptide chains had 
formed the cyclic monomer and 40% had under- 
gone cyclodimerization. The linear analog (3) was 
synthesized by the solid-phase method according 
to the usual protocol based on the coupling of Boc 
amino acids (see [2]). The purification and 
analytical characterization of the cyclic monomer 
(2) have been described [5]. The cyclic dimer (l), 
which had not been isolated before, and the linear 
analog (3) were purified and characterized 
analogously. 
(H-Tyr-D-Lys-Gly-Phe-G\u-NH& (1): TLC Rf; 
0.45 (BAW), 0.68 (BPAW). Amino acid analysis; 
Tyr 1.00, Lys 0.98, Gly 1.01, Phe 1.00, Glu 1.01. 
FAB mass spectrum; MH+ (calculated) 1247, 
(found) 1247. 
H-Tyr-D-Nle-Gly-Phe-Gln-NH2 (3): TLC Rf; 
0.30 (BAW), 0.67 (BPAW). Amino acid analysis; 
Tyr 1 .OO, Nle 1.03, Gly 0.99, Phe 1 .OO, Glu 1.04. 
Binding studies with rat brain membrane 
preparations were performed as described [2], us- 
ing [3H]DAG0 (Amersham) and [3H]DSLET 
(New England Nuclear) at respective concentra- 
tions of 0.71 and 0.98 nM as radioligands. With 
both radiolabels, incubations were performed for 
2 h at 0°C to prevent peptide degradation. Binding 
inhibition constants (Ki) were calculated on the 
basis of Cheng and Prusoff’s equation [7], using 
values of 1.3 and 2.6 nM for the dissociation con- 
stants of [3H]DAG0 and 13H]DSLET, respective- 
ly. The bioassays based on inhibition of electrically 
evoked contractions of the GPI and MVD were 
carried out as reported [2]. A log-dose/response 
curve was determined with [Leu’]enkephalin as 
standard for each preparation and I& values of 
the analogs being tested were normalized as 
described in the literature [8]. Ke values for nalox- 
one as antagonist were determined from the ratio 
of ICso values obtained in the presence and absence 
of a fixed naloxone concentration (5 nM) [9]. 
3. RESULTS AND DISCUSSION 
In the p-receptor representative binding assay 
([3H]DAG0 displacement) the cyclic dimer is 
about twice as potent as [Leu’lenkephalin, about 
g-times less potent than the structurally related 
linear analog (3) and 4-times less potent than the 
cyclic monomer (2) (table 1). Interestingly, both 
the cyclic dimer and the linear correlate have about 
IO-times lower affinity for the a-receptor than 
[Leu’lenkephalin, as indicated by the results ob- 
tained with the [3H]DSLET binding assay, whereas 
the cyclic monomer binds nearly 4-times more 
tightly to the d-receptor than does the natural pep- 
tide. Calculation of the ratios of the binding in- 
hibition constants (Kf/Kf) from these data permits 
an assessment of the opioid receptor selectivity of 
Table 1 
Binding assays of cyclic and linear enkephalin analog? 
No. Compound [3H]DAG0 [3H]DSLET Kf/K; 
Kf’ Wf) Potency ratio Kf (nM) Potency ratio 
1 (H-Tyr-D-Lys-Gly-Phe-Gl,u-NH& 5.33 f 0.48 1.77 + 0.16 23.2 -t 1.3 0.109 f 0.006 4.35 
2 H-Tyr-D-Lys-Gly-Phe-Glu-NH2 1.31 -t 0.21 7.20 -+ 1.15 0.690 * 0.025 3.67 f 0.13 0.527 
3 H-Tyr-D-Nle-Gly-Phe-Gin-NH2 0.628 f 0.037 15.0 + 0.9 23.4 + 2.8 0.108 f 0.013 37.3 
4 [Leu’lenkephalin 9.43 k 2.07 1 2.53 I!Z 0.35 1 0.268 
a Mean of 3 determinations + SE 
232 
Volume 191, number 2 FEBS LETTERS October 1985 
these compounds (table 1). The ratios indicate a 
slight preference of the cyclic dimer for y- over 6- 
receptors and a more pronounced p-receptor selec- 
tivity in the case of the corresponding open-chain 
analog (3). The cyclic monomer is essentially non- 
selective, as reported in [6]. 
In the GPI assay @-receptor epresentative) and 
MVD assay (&receptor representative) the potency 
relationships observed with compounds 1, 3 and 4 
are very similar to those seen in the ,u- and 6- 
receptor-selective binding assays (table 2). The fact 
that 2 is much more potent in the GPI assay than 
would be expected on the basis of its affinity for p- 
receptors may be explained with an increased ‘ef- 
ficacy’ (‘intrinsic activity’) of this compound [6]. 
Since the effects of all analogs on the GPI and 
MVD preparations were readily reversed by nalox- 
one, it is clear that these compounds act via opioid 
receptors. The K, values for naloxone as an- 
tagonist determined with peptides l-4 in the GPI 
assay range from 1.25 to 1.59 nM (table 3). These 
values are typical for p-receptor interactions [lo] 
and rule out a possible additional involvement of 
x-receptors which are also present in this tissue. 
open-chain analog in the [‘HIDAGO binding 
assay. This drop in affinity for the p-receptor may 
be due to the specific conformational constraints 
existing in the dimer. Thus, it is conceivable that 
the conformation(s) of the individual enkephalin 
chains in the dimer might, to some extent, be in- 
duced by hydrogen bonding between 2 moieties on 
opposite chains. In this context it is of interest to 
point out that in one of the crystal forms of 
[Leu’lenkephalin the peptide chains are aligned in 
an antiparallel fashion @-pleated sheet) and linked 
by inter-chain hydrogen bonds [ 121. Alternatively, 
it can be argued that the optimal interaction of one 
of the dimer’s individual enkephalin chains with 
thep-receptor might be impeded by the presence of 
the second covalently linked chain which could 
cause steric interference or interact unfavorably 
with accessory binding sites. The conformational 
constraints present in the cyclic monomer are 
clearly different from those in the dimer and can 
be assumed to be directly responsible for the high 
affinity of compound 2 for both p- and 6- 
receptors. 
It has recently been demonstrated that y- and S- 
opioid receptors differ from one another in their 
conformational requirements [l 11. In view of this 
observation it seems plausible that the differences 
in receptor affinity and selectivity observed be- 
tween analogs 1, 2 and 3 are due to the various 
kinds of conformational constraints introduced in 
the cyclic monomer and dimer through ring forma- 
tion. Since the cyclic dimer and its linear correlate 
(3) are equipotent in the [3H]DSLET binding 
assay, it is obvious that the conformational restric- 
tions present in the dimer do not greatly affect the 
affinity for the b-receptor. On the other hand, 
compound 1 is significantly less potent than the 
The properties of several non-cyclic enkephalin 
dimers have been reported [ 13-171. Dimers 
resulting from linking 2 enkephalin molecules via 
their C-terminal carboxyl groups to linear spacers 
of various lengths showed preference for 6- over I(- 
receptors [16]. It has been suggested that the 6- 
receptor selectivity of these dimers might be due to 
interaction with a bivalent &binding site [ 171. 
However, in the light of the results of the present 
study it could also be argued that the 2 enkephalin 
chains in a folded form of the dimer might interact 
with each other non-covalently such as to generate 
a conformation more compatible with the 6- 
receptor than with the p-receptor. Thus, the 
observed &receptor selectivity could be due to a 
Table 2 
GPI and MVD assay of enkephalin analog? 
No. Compound 
1 (H-Tyr-D-I,ys-Gly-Phe-Glu-NH& 
2 H-Tyr-D-Lys-Gly-Phe-Glu-NH2 
3 H-Tyr-D-Nle-Gly-Phe-Gln-NH2 
4 [Ledlenkephalin 
GPI MVD MVD/GPI 
I&O ratio 
GO 0-M Potency ratio’ IGO WI) Potency ratio 
499 *94 0.493+ 0.093 128 *22 0.0891 kO.0153 0.257 
1.13+ 0.14 218 +27 0.648* 0.132 17.6 k3.6 0.573 
9.08* 0.70 27.1 + 2.1 82.6 + 16.8 0.138 kO.028 9.10 
246 f39 1 11.4 * 1.1 1 0.0463 
a Mean of 3 determinations f SE 
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Table 3 REFERENCES 
Sensitivities to naloxone (ZQ of enkephalin analogs in 
the GPI assaya HI 
No. Compound K, (nM) 
PI 
Schiller, P.W., Eggimann, B., DiMaio, J., 
Lemieux, C. and Nguyen, T.M.-D. (1981) Bio- 
them. Biophys. Res. Commun. 101, 337-343. 
DiMaio, J., Nguyen, T.M.-D., Lemieux, C. and 
Schiller, P.W. (1982) J. Med. Chem. 25, 
1432-1438. 
1 (H-Tyr-D-Lys-Gly-Phe-Glu-NH& 1.29 + 0.06 
2 H-Tyr-D-Lys-Gly-Phe-Gl,u-NH2 1.47 f 0.20 
3 H-Tyr-D-Nle-Gly-Phe-Gln-NH2 1.59 f 0.41 
4 [Let?]enkephalin 1.53 + 0.43 
a Mean of 3 determinations + SE 
conformational effect rather than to a cross- 
linking effect. 
Compound 1 represents the first example of a 
biologically active cyclic peptide dimer of the an- 
tiparallel type obtained through amide bond for- 
mation between side-chains. Antiparallel cyclic 
dimers resulting from disulfide bond formation 
between half-cystine residues have been charac- 
terized as side-products in syntheses of lysine- 
vasopressin [ 181 and oxytocin [ 191. Compared to 
the cyclic monomers these dimers were found to be 
significantly less potent. However, in the case of 
lysine-vasopressin testing in various assay systems 
revealed interesting differences between the cyclic 
monomer and dimer in the overall selectivity pro- 
file [18]. An antiparallel cyclic dimer of the human 
atria1 natriuretic polypeptide, ,@-hANP, has recent- 
ly been isolated from an atria1 extract and shown 
to possess considerable diuretic and natriuretic ac- 
tivity [20]. In all these cases, however, the possi- 
bility of disulfide reduction and subsequent re- 
oxidation resulting in cyclic monomers cannot be 
entirely excluded. In contrast to the cystine-linked 
cyclic dimers the antiparallel cyclic enkephalin 
dimer described in this paper is structurally very 
stable and its distinct opioid activity pattern in- 
dicates that cyclodimerization of this type rep- 
resents a new approach towards manipulating ac- 
tivity profiles of peptide hormones and neuro- 
transmitters. 
ACKNOWLEDGEMENTS 
This work was supported by operating grants 
from the Medical Research Council of Canada 
(MT-5655) and the Quebec Heart Foundation. We 
are indebted to Professor W.J. Richter, Ciba- 
Geigy AG, Basle, Switzerland, for recording the 
FAB mass spectrum of compound 1. 
]31 
141 
PI 
161 
[71 
PI 
[91 
1101 
1111 
WI 
131 
141 
[151 
U61 
1171 
181 
191 
WI 
Mosberg, H.I., Hurst, R., Hruby, V.J., Gee, K., 
Yamamura, H.I., Galligan, J.J. and Burks, T.F. 
(1983) Proc. Natl. Acad. Sci. USA 80, 5871-5874. 
Schiller, P.W., Nguyen, T.M.-D., Maziak, L.A. 
and Lemieux, C. (1985) Biochem. Biophys. Res. 
Commun. 127, 558-564. 
Schiller, P. W., Nguyen, T.M.-D. and Miller, J. 
(1985) Int. J. Peptide Protein Res. 25, 171-177. 
Schiller, P.W. and Nguyen, T.M.-D. (1984) 
Neuropeptides 5, 165-168. 
Cheng, Y.C. and Prusoff, W.H. (1973) Biochem. 
Pharmacol. 22, 3099-3108. 
Waterfield, A.A., Leslie, F.M., Lord, J.A.H., 
Ling, N. and Kosterlitz, H.W. (1979) Eur. J. 
Pharmacol. 58, 1 I-18. 
Kosterlitz, H.W. and Watt, A.J. (1968) Br. J. 
Pharmacol. 33, 266-276. 
Chavkin, C., James, I.F. and Goldstein, A. (1982) 
Science 215, 413-415. 
Schiller, P.W. and DiMaio, J. (1982) Nature 297, 
74-76. 
Karle, I.L., Karle, J., Mastropaolo, D., 
Camerman, A. and Camerman, N. (1983) Acta 
Crystallogr. B39, 625-637. 
Coy, D.H., Kastin, A.J., Walker, M.J., McGivern, 
R.F. and Sandman, C.A. (1978) Biochem. Bio- 
phys. Res. Commun. 83, 977-983. 
Hazum, E., Chang, K.-J., Leighton, H.J., Lever, 
O.W. jr and Cuatrecasas, P. (1982) Biochem. Bio- 
phys. Res. Commun. 104, 347-353. 
Lipkowski, A.W., Konecka, A.M. and 
Sroczynska, I. (1982) Peptides 3, 697-700. 
Shimohigashi, Y., Costa, T., Matsuura, S., Chen, 
H.-C. and Rodbard, D. (1982) Mol. Pharmacol. 
21, 558-563. 
Lutz, R.A., Costa, T., Cruciani, R.A., Jacobson, 
A.E., Rice, K.C., Burke, T.R. jr, Krumins, S.A. 
and Rodbard, D. (1985) Neuropeptides 6, 167-174. 
Schally, A.V., Bowers, C.Y., Kuroshima, A., 
Ishida, Y., Carter, W.H. and Redding, T.W. 
(1964) Am. J. Physiol. 207, 378-384. 
Yamashiro, D., Hope, D.B. and DuVigneaud, V. 
(1968) J. Am. Chem. Sot. 90, 3857-3860. 
Kangawa, K., Fukuda, A. and Matsuo, H. (1985) 
Nature 313, 397-400. 
234 
